共 41 条
- [41] Phase 3 randomized trial evaluating second-line hormonal therapy versus docetaxel-estramustine combination chemotherapy on progression-free survival in asymptomatic patients with a rising prostate-specific antigen level after hormonal therapy for prostate cancer: An Eastern Cooperative Oncology Group (E1899), intergroup/clinical trials support unit study [J]. UROLOGY, 2003, 62 (6B) : 141 - 146